English
Home > Products > 1-N-Boc-3-Hydroxyazetidine

China 1-N-Boc-3-Hydroxyazetidine Factory

We are going to dedicate ourselves to providing our esteemed buyers together with the most enthusiastically thoughtful products and services for 1-N-Boc-3-Hydroxyazetidine,CAS NO 141699-55-0,141699-55-0,Baricitinib intermediate,Baricitinib advance intermediate, We now have substantial goods source and also the rate is our advantage. Welcome to inquire about our merchandise.
1-N-Boc-3-Hydroxyazetidine, We integrate all our advantages to continuously innovate, improve and optimize our industrial structure and product performance. We are going to always believe in and work on it. Welcome to join us to promote green light, together we'll make a better Future!

Related Products

Hot Products

  • 4-Morpholineacetic acid

    4-Morpholineacetic acid

    Product Name:4-Morpholineacetic acid
    Molecular Formula:C6H11NO3
    Molecular Weight:145.16
    CAS Registry Number:3235-69-6
  • Pyrrolo[2,3-d]pyrimidin-4-ol

    Pyrrolo[2,3-d]pyrimidin-4-ol

    Product Name:Pyrrolo[2,3-d]pyrimidin-4-ol
    Molecular Formula:C6H5N3O
    Molecular Weight:135.12
    CAS Registry Number:3680-71-5
  • N-acetyl-10-deacetyl-N-debenzoylpaclitaxel

    N-acetyl-10-deacetyl-N-debenzoylpaclitaxel

    Product Name:N-acetyl-10-deacetyl-N-debenzoylpaclitaxel
    Molecular Formula:C40H47NO13
    Molecular Weight:749.81
    CAS Registry Number:1144034-42-3
  • Varenicline tartrate

    Varenicline tartrate

    Product Name:Varenicline tartrate
    Molecular Formula:C17H19N3O6
    Molecular Weight:361.35
    CAS Registry Number:375815-87-5
  • Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH

    Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH

    Product Name:Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH
    Molecular Formula:C66H105N5O16
    Molecular Weight:1224.59
    CAS Registry Number:2460751-66-8
  • Clinofibrate

    Clinofibrate

    Product Name:Clinofibrate
    Molecular Formula:C28H36O6
    Molecular Weight;468.58
    CAS Registry Number;30299-08-2
  • Related Blog
  • Reviews

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept